RxDoctor Payments Data

Erin Fannin

Nurse Practitioner · Lexington, KYNPI 1275941684

Payments from drug & device makers

$843in general payments, 2019–2025

Across 40 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$193
  • Abbott$149
  • Boehringer Ingelheim$105
  • Vanda Pharmaceuticals Inc.$77
  • Exact Sciences$61
  • AstraZeneca$49
  • plus $210 from 8 others

What the payments were for

  • Food & beverage$843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$843 in reported general payments places this provider in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,730
Medicare patients
59
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl25$48,773
JanuviaSitagliptin Phosphate32$43,220
XareltoRivaroxaban43$38,268
MounjaroTirzepatide22$34,846
EliquisApixaban29$34,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$33,469
JardianceEmpagliflozin25$26,190
OzempicSemaglutide21$22,681
SymbicortBudesonide/Formoterol Fumarate19$9,494
Breo ElliptaFluticasone/Vilanterol13$9,185
MyrbetriqMirabegron16$8,063
Albuterol Sulfate HfaAlbuterol Sulfate147$5,291
Potassium Chloride178$3,502
Varenicline Tartrate18$3,086
Gabapentin280$2,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$193$48,77325 claims
Lilly USA, LLCMounjaro$29$34,84622 claims
PfizerEliquis$16$34,46729 claims
Boehringer IngelheimJardiance$105$26,19025 claims
Novo NordiskOzempic$35$22,68121 claims
AstraZenecaSymbicort$49$9,49419 claims
Astellas Pharma US IncMyrbetriq$19$8,06316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →